- तृप्ति डिमरी और शाहिद कपूर पहली बार करेंगे स्क्रीन शेयर - विशाल भारद्वाज करेंगे फिल्म का निर्देशन
- बॉलीवुड की अभिनेत्रियाँ जिन्होंने सर्दियों के स्टाइल में कमाल कर दिया है
- Akshay Kumar Emerges as the 'Most Visible Celebrity' as Celebrity-Endorsed Ads Witness a 10% Rise in H1 2024
- Madhuri Dixit's versatile performance in 'Bhool Bhulaiyaa 3' proves she is the queen of Bollywood
- PC Jeweller Ltd.Sets December 16 as Record Date as 1:10 Stock Split
Apollo Hospitals Navi Mumbai Extends Cancer Care Consultation to Indore with Launch of Apollo Cancer Clinic in Indore
The Apollo Cancer Clinic will bring advanced treatments and comprehensive care for cancer patients
Indore, 2024: Cancer remains one of the most dreaded non-communicable diseases (NCDs), and its incidence in the state of Madhya Pradesh (MP) is significant. India witnessed a staggering 1.5 million new cancer cases in 2023. There is an average of 1,789 new cancer cases every year in MP, with women accounting for 50.1% and men 49.9% of these cases. By 2025, the projected number of cancer cases in Madhya Pradesh is expected to be 43,097 in males and 45,200 in females. Recognizing this growing concern, Apollo Hospitals Navi Mumbai (AHNM) today launched the advanced Apollo Cancer Clinic to improve access of cancer consultation services to patients in the region.
The Apollo Cancer Clinic located at Apollo Clinic, No 1, Scheme no 44 B, Siddharth Nagar, Bhanwarkua Square, A B Road, Indore will act as a hub for consultations with treating clinicians from Apollo Hospitals Navi Mumbai. These clinicians of national & international standing practice evidence based, organ site specific medicine ensuring the best outcomes for patients.
Present at the launch was Dr. Anil D’Cruz, Director Oncology and Senior Consultant Head & Neck Oncology, an expert in head and neck cancers. Dr. D’Cruz is the former Director of Tata Memorial Hospital, Immediate Past President of the UICC, and a Member of the National Medical Commission. Also present was Dr. Sataksi Chatterjee, Consultant Head & Neck Onco-Surgeon, trained in advanced techniques of head and neck surgery.
Dr. Anil D’Cruz, Director Oncology and Senior Consultant Head & Neck Oncology at Apollo Hospitals, Navi Mumbai, stated,”The rising number of new cancer cases each year underscores the critical need for accessible, high-quality oncology care. Patient outcomes are closely linked to the quality and timeliness of treatment. We are coming to Indore as a team of site-specific specialists led by myself, ensuring focused expertise for each type of cancer. Our consultants are highly trained at leading national and international institutions, practicing within a state-of-the-art, JCI-accredited facility. Our approach emphasizes evidence-based practice and quality care. Our unique offerings include advanced technologies such as TrueBeam STX, IGRT, SBRT, and brachytherapy, along with specialized units like a 9-bed dedicated BMT unit and a 15-bed chemotherapy unit. We also excel in complex and minimally invasive cancer surgeries, including microvascular, laser, and robotic procedures, ensuring comprehensive care for our patients.”
Mr. Arunesh Punetha, Regional CEO – Western Region, Apollo Hospitals said, “The launch of the Apollo Cancer Clinic in Indore marks a significant milestone in our ongoing commitment to bringing world-class healthcare closer to the communities we serve. We are proud to extend our expertise to the people of Indore and the surrounding regions, empowering them in their fight against cancer. We are confident that we will be able to make a significant impact and improve treatment outcomes”
The Apollo Cancer Clinic is well-equipped to diagnose and treat all forms of cancer and aims to set new benchmarks in patient care and research by combining innovative medical approaches with comprehensive supportive services. The clinic will also offer the latest, most promising therapies to patients, including immunotherapies designed to activate the body’s own immune response to cancer and targeted therapies specifically aimed at a patient’s cancer mutations or proteins.